Drug Profile
MP 101 - Mediti Pharma
Alternative Names: LY-2979165; MP-101-Mediti PharmaLatest Information Update: 27 Sep 2022
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Mediti Pharma
- Class Antipsychotics; Dicarboxylic acids; Small molecules; Triazoles
- Mechanism of Action Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- Discontinued Bipolar disorders
Most Recent Events
- 27 Sep 2022 No development reported - Phase-II for Alzheimer's disease (In the elderly, In adults) in Canada (PO)
- 18 Sep 2020 Phase II development is ongoing for Alzheimer's disease (In adults, In the elderly) in USA and Canada (Mediti Pharma website, September 2020)
- 26 Feb 2020 Mediti Pharma terminates a phase II trial in Alzheimer's disease in USA and Canada due to statistical futility (PO) (NCT03044249)